Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

2.04USD
29 Mar 2017
Change (% chg)

$0.14 (+7.37%)
Prev Close
$1.90
Open
$1.88
Day's High
$2.09
Day's Low
$1.88
Volume
163,886
Avg. Vol
37,110
52-wk High
$2.09
52-wk Low
$1.07

VSTM.OQ

Chart for VSTM.OQ

About

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's... (more)

Overall

Beta: 1.92
Market Cap(Mil.): $70.29
Shares Outstanding(Mil.): 36.99
Dividend: --
Yield (%): --

Financials

  VSTM.OQ Industry Sector
P/E (TTM): -- 49.04 30.15
EPS (TTM): -0.99 -- --
ROI: -41.50 -2.17 13.05
ROE: -41.70 5.20 14.20

BRIEF-Verastem reports year-end 2016 financial results

* Expect to have sufficient cash, cash equivalents and investments to fund our research and development programs and operations into 2018

Mar 23 2017

BRIEF-Verastem announces dosing of first patient in Defactinib and Avelumab trial

* Verastem announces dosing of first patient in combination trial of Defactinib and Avelumab in patients with ovarian cancer

Jan 26 2017

BRIEF-Verastem reports Q3 loss per share $0.21

* Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 07 2016

BRIEF-Verastem licenses duvelisib from infinity pharmaceuticals

* Verastem is obligated to pay to infinity up to $28 million in milestones

Nov 02 2016

More From Around the Web

Earnings vs. Estimates